We evaluated the effects of a new non-steroidal anti-inflammatory
drug (
NSAID), d-2-[4-(3-methyl-2-thienyl)phenyl]
propionic acid (M-5011), and
indomethacin on the production of arachidonate metabolites and pro-inflammatory
cytokines in male Sprague-Dawley rats with
monosodium urate crystal (MSU)-induced
pleurisy. Levels of
tumor necrosis factor (TNF),
interleukin (IL)-1 and
IL-6 in the pleural exudate were determined by
biological assays, while
prostaglandin E2 (
PGE2),
leukotriene B4 (
LTB4) and
cytokine-induced chemoattractant-1 (CINC-1) levels were quantified by
enzyme immunoassays. Orally administered
M-5011 (5 mg/kg) decreased the pleural exudate volume at 3 and 4 hr after MSU injection.
Indomethacin (10 mg/kg) decreased the volume at 3-5 hr. These drugs reduced the number of leukocytes in the pleural cavity at 6 hr. Both
NSAIDs also reduced the content of
PGE2 in the exudate without affecting
LTB4 levels. Increased productions of both
IL-6 and CINC-1 in the exudate were reduced by pretreatment with
M-5011 or
indomethacin, and TNF levels in the exudate were increased by pretreatment of these drugs. Thus,
M-5011 inhibits the production of both
IL-6 and CINC-1 at lower doses than those of
indomethacin, and the inhibitory effect of
M-5011 on CINC-1, but not
IL-6, may partly contribute to the inhibition of leukocyte infiltration in rats with MSU-induced
pleurisy.